Review

Unraveling Alzheimer’s: Exploring the Gut Microbiota–Brain Axis as a New Frontier in Understanding

Shahzada Mudasir Rashid 1,2,*, Rahil Razak 2, Aabid Khaliq Tantray 3, Antonisamy William James 1, Nuzhat Showkat 2, Faheem Shehjar 1, Fatimah Jan 4, Sheikh Bilal Ahmad 2, Andleeb Khan 5, and Zahoor A. Shah 1,*

1 Department of Medicinal and Biological Chemistry, Collage of Pharmacy and Pharmaceutical Science, The University of Toledo, Toledo, OH 43614, USA; awJames01@gmail.com (A.W.J.);
faheem.shehjar@utoledo.edu (F.S.)
2 Division of Veterinary Biochemistry, Faculty of Veterinary Science and Animal Husbandry, SKUAST-Kashmir, Alustang, Shuhama 190006, Jammu & Kashmir, India; rahilrazak192@gmail.com (R.R.);
nuzhatshowkatlone@gmail.com (N.S.); sbilal@skuastkashmir.ac.in (S.B.A.)
3 College of Temperate Sericulture, SKUAST-Kashmir, Srinagar 190006, Jammu & Kashmir, India; aabidseri@skuastkashmir.ac.in
4 Department of Pharmaceutical Chemistry, Sufiya College Pharmacy, Rajasthan University of Health Sciences, Nagaur 341001, Rajasthan, India; fatimahjan0088@gmail.com
5 Department of Biosciences, Integral University, Lucknow 226026, Uttar Pradesh, India; drandleebkhan@gmail.com
* Correspondence: mudasir@skuastkashmir.ac.in (S.M.R.); zahoor.shah@utoledo.edu (Z.A.S.)

Abstract: The gut microbiota (GM) communicates with the brain via biochemical signaling constituting the gut–brain axis, which significantly regulates the body’s physiological processes. The GM dysbiosis can impact the digestive system and the functioning of the central nervous system (CNS) linked to the onset of neurodegenerative diseases. In this review, the scientific data compiled from diverse sources primarily emphasize the neuropathological characteristics linked to the accumulation of modified insoluble proteins (such as β-amyloid peptides and hyperphosphorylated tau proteins) in Alzheimer’s disease (AD) and the potential impact of gut microbiota (GM) on AD susceptibility or resilience. The specific GM profile of human beings may serve as an essential tool for preventing or progressing neurodegenerative diseases like AD. This review focuses mainly on the effect of gut microfauna on the gut–brain axis in the onset and progression of AD. The GM produces various bioactive molecules that may serve as proinflammatory or anti-inflammatory signaling, contributing directly or indirectly to the repression or progression of neurodegenerative disorders by modulating the response of the brain axis. Human studies must focus on further understanding the gut–brain axis and venture to clarify microbiota-based therapeutic strategies for AD.

Keywords: Alzheimer’s disease; neurodegenerative disorders; β-amyloid; tau protein; gut microbiota brain axis

1. Introduction

The term “human microbiota” refers to the collection of tiny creatures inhabiting a specific habitat, including protists, bacteria, fungi, archaea, and viruses. Specific microbiomes in the body are found in organs like the lungs, skin, and gastrointestinal system. The gastrointestinal tract (GIT) microbiota, or bacteria, has been the subject of the most scientific research among these ecosystems. The microbiota, which consists of commensal (or potentially pathogenic) bacteria, is found on the surfaces of the mucosal membranes and in the lumen of GIT. Over 90% of the species of bacteria in the GIT belong to the Firmicutes and phyla Bacteroidetes, with very few amounts of Proteobacteria, Actinobacteria, and Verrucomicrobia [1].
The gut–brain axis is a bidirectional, biochemical signaling interaction between the brain and gastrointestinal system. The GM plays a role in physio–biochemical signaling events involving the duo’s participation. Hence, it is also referred to as the Microbiota–Gut–brain (MGB) or Brain–Gut–Microbiota (BGM) axis [2]. The integrative physiology of the MGB axis involves the participation of the central nervous system (CNS), autonomous nervous system, hypothalamic pituitary adrenal axis, enteric nervous system, intestines, and other organs to orchestrate response that influences the functioning of gut cells, such as epithelial, smooth muscle, immune, enteric chromaffin and other cells (Figure 1) [3]. The gut and brain work in close coordination, influencing each other’s functioning due to their common origin from the tissue—the neural crest [4]. They perform abundant physiological functions, including food intake, satiety, bone metabolism, insulin secretion, responsiveness, glucose, and fat metabolism [5]. The mucosal barrier of the intestine comprises the intestinal epithelial layer, mucosal layer, and microorganisms. The microorganisms constituting the GM influence the proper functioning of the intestinal mucosa and epithelial cells. However, GM dysbiosis has an impact on the digestive system and the functioning of the CNS. The microorganisms that help compensate the intestinal flora may otherwise have a significant capacity for secreting amyloid and lipopolysaccharides (LPS), which may affect signaling pathways as well as the generation of proinflammatory mediators connected to the initiation of AD [6].

**Figure 1.** Integrative physiology of MGB axis (CNS-central Nervous System, ENS-Enteric Nervous System, HPA-Hypothalamic Pituitary Adrenal Axis).

AD pathogenesis can be explained by different hypotheses, including the amyloid cascade hypothesis (ACH), tau hyperphosphorylation or accumulation of neurofibrillary tangles, and oxidative stress. The development of Alzheimer’s disease (AD) involves complex molecular and cellular mechanisms. Extracellular amyloid β (Aβ) protein, which forms senile plaques (SP) and intracellular neurofibrillary tangles (NFTs) made up of phosphorylated tau (p-tau) protein, are well-known pathological features of AD. Additionally, neuroinflammation has been shown to contribute significantly to the disease progression.
of AD. Other contributing factors include cerebrovascular amyloidosis and alterations in synaptic function. Collectively, these pathological changes disrupt the delicate balance of cellular pathways and ultimately lead to cognitive decline and other symptoms of AD. Other factors, such as aging, genetics, lifestyle, viral and bacterial infections, etc., may also affect AD pathogenesis [7–10]. The gut–brain axis is a bidirectional communication path between the CNS and gastrointestinal tract. Moreover, the LPS produced and secreted by pathogenic GM is regarded as one of the factors of gut dysbiosis characterized by an imbalance between eco-friendly and pathogenic GM. LPS from dead bacteria are far more ubiquitous in the microbiota-associated composition with AD. LPS stimulates enteric signaling pathways, producing the proinflammatory cytokine-nuclear factor kappa-B (NFk-B). NFk-B acts as a precursor for the production of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Studies have revealed the ability of LPS to enter the bloodstream from the digestive tract and activate astrocytes and microglia in the brain, which promotes neuroinflammation in brain tissues.

The blood–brain barrier (BBB) is formed by endothelial cells, pericytes, and mural cells from the perivascular region. It controls molecular exchange in the intricate networks of the brain’s microvasculature. Larger molecules, like proteins, peptides, and highly harmful blood-related substances, are blocked from entering the brain by the BBB, but nutrients like sugars and proteins can be transported from blood to the brain and back and are managed by carrier-derived bidirectional trans-endothelial transfer [11]. The interaction of several neurovascular unit cell types regulates the integrity of the BBB, cerebral blood flow, and several other CNS activities. The normal integrity of BBB plays a major role in preventing the entry of bioactive harmful substances released from GM, which will otherwise lead to CNS damage. Through the neuroendocrine pathway, microbiota metabolism can also directly control the synthesis of neurotransmitters. The microbiota–gut–brain axis is indirectly impacted by the metabolites produced in the intestinal tract that diffuse into the host body, modulating the BBB and innate immune activation. As evident from various scientific findings, gut microbes play an essential role in maintaining the homeostasis of the brain by secreting some bioactive molecules [12]. However, during gut dysbiosis, some nonimportant molecules that are produced serve as agents for the development and progression of AD by altering the immune status and physiology of neurons and glial cells [13]. Gut microbiota are directly involved in maintaining the neuroendocrine secretory pathway as well as neuroimmune status. Yunes et al., in 2016, showed that Lactobacillus and Bifidobacterium can directly produce γ-aminobutyric acid (GABA), while as Serratia and Escherichia are associated with the production of dopamine, both these neuroactive molecules take part in the modulation of neuroendocrine signaling and, therefore, maintaining the homeostasis of brain [14]. For the development of AD, there are different bioactive molecules associated with the microbiome gut–brain axis like microbial secretory products (LPS from Bacteroides fragilis [15], Microbial amyloid from Escherichia coli; Salmonella enterica; polysaccharide A from Bacteroides fragilis and metabolism-related products (SCFAs from Ruminococcus bromii (butyrate), Faecalibacterium prausnitzii, Eubacterium rectale, Eubacterium hallii and R. bromii (major fraction of butyrate production) and Akkermansia muciniphila (propionate)) [14].

Butyrate (SCFA), in particular, is known to enhance the integrity of the blood–brain barrier and reduce neuroinflammation, which may help mitigate the progression of AD [16]. Indole-3-propionic Acid, Indole-3-acetic Acid [17], Phenylacetic Acid, and Phenylpropionic Acid compounds are produced by the metabolism of polyphenols by gut microbiota. These compounds possess antioxidant and anti-inflammatory properties, which may help protect against neuroinflammation and oxidative stress in AD [18]. Gut bacteria can produce neurotransmitters (GABA and 5HT) and their precursors, which have the capability to alter brain function. GABA has inhibitory effects on the nervous system and can reduce neuronal excitability, potentially mitigating the effects of AD. Serotonin, produced from tryptophan, can influence mood and cognitive functions [19].
With the advancement of scientific research in neuroinflammation, a wide contribution of GM has been found to be associated with the interference of the brain’s physiological processes. Any disturbance in the gut–brain axis negatively impacts the pathogenesis of neurodegenerative diseases. Shifting of the balanced and stable state of the GM composition directly affects the permeability of the blood–gut barrier, which leads to the passage of GM-released bioactive substances and, subsequently, activation of the enteric immune system [20]. In aged individuals, an activated systemic immune system significantly promotes neural injury and, finally, neuroinflammation, also known as “inflammaging” [21]. In germ-free mice (GFM), it has been found that the gut microbe composition significantly influences early CNS development and neurogenesis [22]. Reports from various scientific sources prove that the typical pathognomic lesions, such as the accumulation of p-tau proteins intracellularly and amyloid β fibrils, are associated with the change in the constitution of gut microflora [23]. Therefore, there is a need to develop comprehensive knowledge of GM and its role in the development of neuroinflammation.

Diet is an essential determinant of the type and role of GM in human beings. Diet plan and composition are closely related to the development of AD [24]. Dietary pattern is an adaptable factor for the amelioration of microbiota. Neuroprotection is linked with the Mediterranean diet and the Ketogenic diet (KD). Probiotics, prebiotics, and fecal microbiota transplantation (FMT) may be potential therapeutics for AD and other neuroinflammatory conditions [25]. The current research review article exclusively emphasizes the bidirectional communications of faunal life residing in the gastrointestinal tract with the brain and the effects of their shifts toward the development of AD in humans, which is exclusively associated with neurodegeneration.

2. Gut–Brain Axis Dysbiosis in AD Development

The role of distinct GM serves as one of the essential innovative ways of studying the functioning of the gut–brain axis (GBA); this bidirectional connection with the brain is termed the MGB axis (Figure 1). MGB refers to a bidirectional communication between the brain and the gut involving multiple overlapping pathways, including the autonomic, neuroendocrine, vagus nerve, the immune system, or the metabolic processes of GM and the immune system in addition to bacterial metabolites and neuromodulatory molecules [26,27].

Biological research output related to AD and the role of GM with the onset of AD are still in their initial stages. In the last few decades, neuroscientists have been working tirelessly to find the exact cause of this neurodegenerative disease, which remains a puzzle, nevertheless, recent scientific data reveal its occurrence commences ten years before the appearance of clinical symptoms [28]. Metchnikoff, a noble laureate in immunology, hypothesized about the diverse role of bacteria with few residing in the colon of human beings possessing beneficial effects on human health while some others show negative effects (pathogenic). Under normal physiological conditions, the gut microflora (GM) plays a role in promoting proper immune maturation and serves as a source of essential nutrients for the host. However, dysbiosis, which refers to an imbalance in the composition of beneficial and pathogenic GM, has been associated with the development of various diseases, including AD.

There is significant linkage between the gastrointestinal tract, its GM and the brain via bidirectional communications. The signaling mechanisms include top-down (brain → gut) and bottom-up signaling (gut → brain). Top-down signaling proceeds directly via sympathetic and parasympathetic neurons or indirectly by stimulating the enteric nervous system located in the submucosa and myenteric plexi in the gut wall [29]. Alterations in gut microbiota leading to neuroinflammation in the brain are closely associated with the development of AD, which follows the progressive degenerative pathways leading to alteration/increase in permeability of the gut barrier and activation of active cellular components of the immune system that harm blood–brain functions, promote neuronal injury, neuroinflammation, and, finally, development of AD [21]. The GM is well known as
the origin of an abundant amyloid, LPS, and other toxic chemicals; therefore, microbiota predisposes animals to systemic inflammation and disruption of physiological barriers [21]. Microbiota inhabited in the human gut not only assist gut-specific activities like the fermentation of carbohydrates for byproduct formation, vitamin synthesis, and detoxification of xenobiotics [22,23] but also act as a protective tool against the pathogenic bacteria in the gut [30] and maintain the neuronal health of an individual.

Based on clinical and preclinical studies, the production of some biomolecules, like neuromodulators and neurotransmitters, from GM has a direct impact on gut–brain communication, behavioral changes and brain activities [31–34]. The released bioactive chemicals/transmitters of GM can intrude from the GIT to the brain or spinal cord, especially during old age, which can activate the abnormal formation of amyloid protein with enhanced aggregation [21]. The GM products can activate immune cells, boosting inflammatory response in the brain, which in turn influences immune cells like microglial cells function. Activated microglial cells induce neuroinflammation in the CNS, resulting in neuron damage, which is a major factor contributing to AD development. The two characteristic pathological lesions of AD, i.e., extracellular amyloid plaques and neurofibrillary tangles, are composed of mainly Aβ and p-tau proteins, respectively [35].

A rat model study based on Bifidobacterium infantis, one of the essential microorganism, indicated that the gut microbe has a significant connection to the immune response in the brain [31]. An increase in the number of Lactobacillus casei, Bacteroides fragilis, and Streptococcus thermophiles in the rodent intestine revealed a positive effect on brain activity and performance [31,36,37]. On the other hand, Eubacterium rectale, Porphyromonas gingivalis, and Lactobacillus rhamnosus may contribute to the pathogenesis of AD [38–43].

GM like Escherichia, Lactobacillus, Saccharomyces, and Bacillus are actively involved in the synthesis of gamma-amino butyric acid (GABA), 5-hydroxytryptamine, dopamine, butyrate, histamine, and serotonin, which play an important contributing role in regulating the brain activity of an individual after entering the mucosal layer of the intestine and, successively, are capable of entering the bloodstream (Table 1) [44–46]. A decreased population of microbiota in aged individuals with brain pathology has been associated with lower levels of butyrate, which in turn predisposes other brain injuries and progressive cognitive loss [47]. Recently, it was revealed that AD could be initiated even in the gut and progress toward the brain due to the translocation of αβ oligomers [48].

<table>
<thead>
<tr>
<th>Reference</th>
<th>Subject</th>
<th>Bacteria/Organism</th>
<th>* Effects (+/-)</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>[49]</td>
<td>AD patients</td>
<td>Bacteroides fragilis</td>
<td>+</td>
<td>Protection against CNS demyelination diseases [49].</td>
</tr>
<tr>
<td>[50]</td>
<td>C57BL/6 mice</td>
<td>+</td>
<td>Pregnant mice showed an immediate significant diminished autistic behavior [50]</td>
<td></td>
</tr>
<tr>
<td>[42]</td>
<td>AD patients</td>
<td>Eubacterium rectale</td>
<td>−</td>
<td>Leads to amyloidosis [42]</td>
</tr>
<tr>
<td>[51]</td>
<td>BB-DR rats Healthy humans</td>
<td>Lactobacillus johnsonii</td>
<td>+</td>
<td>Improved gastric vagus nerve activity [51].</td>
</tr>
<tr>
<td>[41]</td>
<td>AD patients</td>
<td>Porphyromonas gingivalis</td>
<td>−</td>
<td>Responsible for cirrhosis, which leads to neurodegeneration [41]</td>
</tr>
<tr>
<td>[52]</td>
<td>SAMP8 mice</td>
<td>Lactobacillus acidophilus</td>
<td>+</td>
<td>Enhanced the injury in neural proteolysis [52].</td>
</tr>
<tr>
<td>[40]</td>
<td>C57BL/6 mice</td>
<td>Campylobacter rodentium</td>
<td>−</td>
<td>Led to stress and contributed to behavioral abnormalities [40].</td>
</tr>
<tr>
<td>[38]</td>
<td>Wistar rats</td>
<td>Lactobacillus rhamnosus</td>
<td>+</td>
<td>Improved the inflammation level in the brain [38].</td>
</tr>
</tbody>
</table>

* +: Signifies a protective role against neuroinflammation, −: suggests involvement in the onset of neuroinflammation. |
2.1. Bridge between Neuroinflammation and Microbiota Dysbiosis

The research suggests that there is a supplementary relationship between the immune system and GM. The immune system plays a role in regulating the composition and structure of the GM, while GM influences the maturation and function of the immune system [53,54]. Numerous studies have shown that antibiotic-treated or germ-free mice (GFM) possess lower ratios and impaired differentiation capabilities of myeloid cell progenitors, indicating that the GM influences immune system development [55]. Additionally, the absence of GM in mice or germ-free rodents can lead to altered gene expression in immune cells like microglia, resulting in dysregulation of immune system-related defense activities such as pathogen recognition and cell activation [56].

AD is included in one of the tautopathies characterized by the formation of neurofibrillary tangles composed of p-tau proteins [57]. Tau is a water-soluble protein associated with the stability of axonal microtubules [58]; if it is detached from these microtubules, it results in the loss of synopsis and neuronal death [57]. According to the tau hypothesis, altered tau protein deposits stimulate neurodegenerative diseases, as found in AD [57]. On a molecular level, tau proteins are microtubule-associated proteins that assist in axonal transport and microtubular stability [59]. Tau’s inflection of tubulin assembly and stability is regulated by its degree of phosphorylation. In neuroinflammatory processes, such as AD, Tau protein undergoes hyperphosphorylation, leading to its conformational change over into \( \beta \)-sheet rich structures, forming large and insoluble tangles [60]. During pathological conditions, there is a depolymerization of microtubules due to hyperphosphorylation of tau proteins, which disintegrates them from each other, leading to the p-tau protein aggregations and, characteristically, the formation of neurofibrillary tangles (NFTs) inside the neurons [61]. By the age of 40 years, there is an increase in the concentration of p-tau and total tau (t-tau) proteins inside neurons [62], which block the transport of nutrients into the neurons, leading to cell death and hampering with nutritional transport in neurons. The altered tau proteins are responsible for the activation of microglial cells; and they can spread in a prion-like fashion, resulting in neuronal and synaptic anomalies [63]. Recent studies have shown that disturbances in insulin-mediated molecular pathways are also associated with AD pathogenesis [64]. The binding of insulin-to-insulin receptors leads to the activation of various insulin receptor substances (IRS), which activate downstream signaling pathways, including phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) cascades that regulate various physiological processes [65]. While progressing the PI3K pathway, there is phosphorylation of glycogen synthase kinase (GSK) \( \beta \), which deactivates it. GSK \( \beta \) regulates tau phosphorylation, which contributes to the formation of NFTs. Activation of GSK \( \beta \) could thus induce hyperphosphorylation of tau proteins, contributing to the development of AD [66].

GM secretes an abundant number of metabolites, which mainly include valeric acid, isovaleric acid, isobutyric acid, butyric acid, propionic acid, acetic acid and formic acid and their effects on the pathogenesis of AD have been explored by disturbing the activations of microglia and astrocyte, help to reduce inflammation, and aggregations of A\( \beta \) and tau proteins [67]. After proof from the meta-analysis, various studies have indicated that the bioactive chemicals released from GM can increase the degree of inflammation, tautopathies and A\( \beta \) aggregation in CNS [68].

Moreover, tau hyperphosphorylation has been found to be facilitated by IL-1 via the MAPK pathway, IL-6 via cyclin-dependent kinase 5 pathway and NO compound [69,70]. Data related to microbiome effects on gut–brain health implies a decrease in the levels of proinflammatory cytokines, such as IL-1\( \beta \), IL-6, TNF-\( \alpha \), and TNF-\( \beta \) [60], whose increased levels have been found to be associated with neurological disorders [71]. Thus, these results suggest a close association between the immunomodulatory action of GM-released proinflammatory cytokines and neuroinflammation [72]. Clinton et al. (2010) studied the cross-interaction between the different proteins of amyloid plaques in AD and reported a mutual interaction of tau protein with A\( \beta \) proteins [73]. Microglia maturation plays a crucial role in limiting the concentration of p-tau proteins, thereby reducing the chances...
of AD. Erny et al. (2015) studied the inflammation of the brain in GFM where they found an increase in the number of microglia; however, after treatment of these GFM with lipopolysaccharide (LPS), an agonist of transmembrane immune system-associated receptor, TLR4, they observed an increased microglia maturation with reduced levels of chemokines and cytokines [74].

The role of microglia activation and reduction in p-tau proteins under physiological conditions is investigated. Bacterial amyloids facilitate the clearance of Aβ aggregates and hyperphosphorylated tau proteins by microglia cells through the receptor of microglia/myeloid-2 cells (TREM-2). This suggests that bacterial amyloids may play a role in the regulation of protein aggregation in the brain, potentially influencing the neurodegenerative process. (TREM-2) [75].

2.2. Blood–Brain Axis Alteration by GM

The term “gut microbiota–blood–brain axis” describes a two-way network of information that consistently exchanges information between the neurological and digestive systems [76]. It is widely acknowledged that the intestinal microbiota has an impact on the physiological, behavioral, and cognitive processes of the brain (Table 2). The parasympathetic and sympathetic–autonomic neurological networks, the nervous system, metabolic waste GM, the neuroendocrine system, the immune system of the nervous system, and the CNS may be included in this. Other potential communication channels in the GM and brain, including the BBB and the intestinal mucosal barrier, neuroendocrine adrenal axis, pituitary and hypothalamic, the immune system of the gut, neurotransmitters, and regulators of neural activity, are produced by the bacteria of the gut [76]. Our metabolism, digestion, nutrition, growth, immunology, and defense against infections all depend largely on the human microbiota [77–79]. The easiest way to understand how microbiota affects immunity is from the perspective of evolution, as it serves the microorganism’s adaptive interest to keep the host in a state allowing for colonization. The complex molecular progression has preserved the host to preserve immunological tolerance due to the utmost importance of microorganisms for human existence. The term “brain–gut–microbiota axis” was expanded due to the significance of the microbiota’s impact on the brain [80].
<table>
<thead>
<tr>
<th>First Author, Journal Year</th>
<th>Animal Model</th>
<th>Exposure</th>
<th>Outcome Measured</th>
<th>Main Results</th>
<th>Proposed Mechanism of Intestinal Microbiota Involvement in Dementia Physiopathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>[81] Harach, Sci Rep, 2017</td>
<td>APPPSI transgenic mice</td>
<td>Mice that are germ-free thanks to IVF and are raised in a sterile environment</td>
<td>Cerebral amyloid deposition</td>
<td>Germ-free mice have less cerebral amyloid deposition than controls, whereas germ-free mice who received fecal microbiota transplants from controls have more amyloid deposition.</td>
<td>Bacteria in the gastrointestinal tract may cause subclinical brain inflammation that facilitates the deposition of amyloid.</td>
</tr>
<tr>
<td>[82] Minter, Sci Rep, 2016</td>
<td>APPSwe/PSIΔE9 Transgenic mice</td>
<td>Long-term broad-Spectrum combinatorial antibiotic therapy</td>
<td>Aβ amyloid deposition soluble Aβ levels cerebral glial reactivity Circulating cytokine and chemokine level</td>
<td>Mice given antibiotics had higher levels of circulating cytokines and chemokine’s, less cerebral A-plaque formation, and higher levels of glial activity and circulating A.</td>
<td>Gut dysbiosis may have beneficial effects during the acute phase (reduced A plaque deposition), but negative effects during the long term.</td>
</tr>
<tr>
<td>[83] Minter, Sci Rep, 2017</td>
<td>APPSwe/PSIΔE9 Transgenic mice</td>
<td>Postnatal antibiotic treatment</td>
<td>makeup of the gut microbiome Brain deterioration Foxp3+ Inflammation caused by T-reg cells in the blood, brain serum, and cerebrospinal fluid</td>
<td>Post-antibiotic therapy led to stable changes in GM diversity, including a decrease in species richness and an increase in Lachnospiraceae representation, an upregulation of circulating and brain Foxp3+ Treg cells, and a decrease in the breakdown of brain A-amyloid.</td>
<td>Through the synthesis of butyrate and the differentiation of T-cells into Foxp3+ Treg cells, the GM may mediate neuroinflammation.</td>
</tr>
<tr>
<td>[84] Frohlich, Brain Behav Immun, 2016</td>
<td>Adult mice</td>
<td>Intragastric treatment with multiple antibiotics</td>
<td>colon’s metabolic profile circulation microbial metabolites expression of signaling molecules in neurons Cognitive Conduct</td>
<td>Enhanced cytokine representation in the amygdala and hippocampus, decreased neuronal signaling-related chemicals in the brain, decreased colonic and circulating microbial metabolites, and worse novel object recognition memory are all indicators of GM dysbiosis.</td>
<td>Depletion of microbial metabolites in the gut may function as endocrine messengers, affecting the synthesis of neutral signaling molecules, particularly in the amygdala and hippocampus (BDNF, NMDA receptor, serotonin transporter, and NPY).</td>
</tr>
<tr>
<td>[85] Cui, BBA Mol Basis Dis, 2017</td>
<td>C57BL/6j mice</td>
<td>Total abdominal irradiation</td>
<td>circulating and intestinal miRNAs Expression of BDNF in the brain and gut microbiome</td>
<td>Cognitive impairment brought on by radiation, dysbiosis of the gut microbiome, overexpression of the circulating miR-34a-5p gene, and decreased expression of the brain protein BDNF GM eubiosis and BDNF synthesis were restored by injection of miR-34a-5p antagonists.</td>
<td>GM may influence the expression of miRNAs, specifically miR-34a-5p, which may mediate a bidirectional gut–brain interaction.</td>
</tr>
</tbody>
</table>

**Abbreviations:** Treg, T regulatory; IVF, in vitro fertilization; BDNF, brain-derived neurotropic factor; NPY, neuropeptide Y.
Under normal circumstances, low-density lipoproteins of receptor-derived protein 1 transport dissolved amyloid beta (A) in the reverse direction from the circulatory system to the nervous system [86]. Postmortem investigations performed on AD patients revealed BBB damage and an accumulation of capillary substances in the nervous system [87]. This process was supported by MRI scans of the human brain, which revealed an age-dependent blood–brain protective narrowing in the hippocampus, a region responsible for memory and learning. The breakdown that Cerebrospinal fluid (CSF) analysis linked to pericyte damage was more severe in mild cognitive impairment. Pericyte destruction is accelerated by the E gene 4 apolipoprotein alleles, which are the primary genetic susceptibility factors for AD [88].

According to certain studies, stress during a child’s formative years may change the microbiota, which raises the risk of stress-related disorders later in life [89,90]. Maternal separation three days after birth caused a reduction in Lactobacillus levels in the baby rats, which had a large effect on the gut microbiota [89]. Prenatal stress altered the microbiome of rhesus monkeys by decreasing the overall concentration of Lactobacillus and Bifidobacterium [91]. The incidence of experimental colitis in children was also increased by prenatal antibiotic use [92]. These results revealed stress might alter the flora in the gut. A neurovascular unit is made up of glial cells (microglia and astrocytes), vascular endothelial cells, neurons, and pericytes [11].

Permeability of the BBB and the gut–blood barrier is highly influenced by microbial dysbiosis, which serves as a predisposing factor for neurological disturbances, such as the progression of AD pathogenesis and other neurodegenerative diseases, especially those linked to aging. The integrity of the BBB is inadequate, enabling LPS to transfer through it and leading to inflammation in the brain. As a result, a thorough understanding of GM and their role in the development of brain inflammation is required (Figure 2). The endothelial cells of the brain and pericytes create the BBB, which safeguards the brain and nervous system from blood-derived chemicals, infections, and cells [86]. Modern research on transgenic mouse models has demonstrated the importance of pericytes in regulating BBB integrity, and its loss can contribute in the genesis of small vessel diseases of long-term BBB collapse and neurodegenerative alterations [93–95]. Multiple investigations have shown that the apolipoprotein E4 (apoE4) genotype accelerates the loss of integrity of the cerebrovascular system and BBB impairment in AD [96–98]. Three main apoE isoforms exist in humans: E2, E3 and E4. Genetic evidence, particularly new genomic sequence linkage analyses, indicates apoE4 is the most important and increasingly recurrent genetic potential risk factor for AD. A single apoE4 copy confers approximately a 3.7-fold increased risk of AD compared to two copies, which confers a 12-fold increased risk compared to carriers of the apoE3/E3 genotype. Research utilizing transgenic mice has shown that apoE4 enhances BBB sensitivity to injury, induces BBB breakdown, and decreases microvascular concentration compared to apoE3 mice [99].

The exact etiology involved in the breakdown of BBB in AD, especially in apoE4 individuals, is still unknown. Inhibition of the cyclophilin A proinflammatory (CypA)-metalloproteinase-9 (MMP-9) mechanism throughout pericytes through reduced lipid receptor-derived peptides-1 (LRP1), a crucial apoE binding site, astrocyte-released apoE2 as well as apoE3, were shown to preserve the integrity of the blood–brain protective layer in recent research utilizing transgenic apoE2 as well as apoE3 models of mice [100,101]. The CypA-MMP-9 system is ineffectually inhibited by astrocyte-released apoE4 in the apoE4 mouse models, which leads to MMP-9-derived degradation of the BBB firm connection, causing basal lamina proteins as well as BBB breakdown [102]. Additionally, a recent study contrasting cognitively normal healthy apoE4 transport to apoE3 providers found a dependence of age and an active MMP-9 concentration in the CSF, suggesting activation of the CypA-MMP-9 route. This raised ratio of CSF to plasma albumin indicates BBB collapse and is found to correlate with the CypA-MMP-9 signaling pathway [103]. Here, researchers use postmortem human brain tissue analysis as an indicator of BBB collapse to evaluate that apoE4, compared to apoE3, increases pericyte losses as well as microvascular abnormalities
in the disease of AD and correlates with the amount of BBB disintegration to molecules like immunoglobulin G and fibrin. apoE4 generates a larger aggregation of CypA and MMP-9 in endothelial cells and pericytes in AD relative to apoE3, indicating a higher stimulation of the LRP1-dependent CypA-MMP-9 BBB-mortifying mechanisms. The loss of pericytes may also contribute to apoE4’s elevated CypA and MMP-9 build-up, which may hasten BBB rupturing in AD apoE4.

**Figure 2.** Illustrative diagram represents the microbial gut dysbiosis leading to production of proinflammatory cytokines, nonindispensable harmful metabolites and changes in neurotransmitter production that contribute toward the development of AD. The metabolite diversity in gut dysbiosis increases the intestinal permeability and mucous secretion due to the disruption of tight junctions and inflammation of epithelial intestinal cells, respectively. Such metabolites may serve as biomarkers for development of AD in serum and feces. The Ab and tau proteins that travel via the vagus nerve and are produced from GMD are also responsible for development of AD. (AD, Alzheimer’s Disease; GMD, gut microbial dysbiosis; Ab, amyloid beta, PIC, proinflammatory cytokines; SCFA, short chain fatty acids; LPS, lipopolysaccharide; BBB, blood–brain barrier).

3. **Mechanism of Brain and Intestinal Blood–Barrier Interaction in Alzheimer’s Disease**

The gut immune barrier GIB permanently contains the microbiota, sometimes called innocuous microbial flora and food antigens, which are essential for digestion and act as the first line of defense in the event of an attack by invasive infections [104]. The mucosal barrier of the intestine is made up of the intestinal epithelial layer, mucosal layer, and microorganisms. The mucous barrier, which is composed of mucin molecules secreted by goblet cells, protects the epithelial layer from infections by acting as a barrier. Proteins of tight-junction like occludin, claudins, and adhesion of junctional cells or kitricellulin join the epithelial tissues. The microbiota improves the viability of the intestinal mucosa as they indirectly produce SCFAs and stimulate the proliferation of epithelial cells. The ability of intestinal epithelial cell monolayers to become more permeable by the proinflammatory...
cytokines IL13, TNF, IL6, IL4, and IL13 has been associated with higher production of claudins [105].

Specific microbiomes in the body can be discovered in organs like the lungs, skin, and gastrointestinal system. The GIT microbiota, or bacteria, has been the subject of the most research among these ecosystems. The microbiota, which consists of commensal (or potentially pathogenic) bacteria, is found on the surfaces of the mucosa and in the lumen of the GIT lumen. Over 90% of the species of bacteria in the GIT belong to the Firmicutes and phyla Bacteroidetes, with very small amounts of Proteobacteria, Actinobacteria, and Verrucomicrobia [1].

Our gastrointestinal ecosystem is a diverse population of microbial species called GM, whose modifications can impact both digestive illness and CNS diseases like AD. The altered permeability of the BBB and gut, due to microbial dysbiosis, also acts as a mediator or impacts the pathogenesis of AD and other neurodegenerative diseases, especially those linked to aging. The microorganisms that help compensate the intestinal flora also have a significant capacity for secreting amyloid and lipopolysaccharides, which may affect signaling pathways and the generation of mediators of proinflammatory response connected to the initiation of AD [6].

LPS models for neuropathology in AD Bactericides that create LPS are far more ubiquitous in the microbiota composition associated with AD. When LPS stimulates enteric signaling pathways to produce IL-1, IL-6, and tumor necrosis (TNF), the nuclear factor kappa-B (NF-κB) pathway is activated, which increases the production of proinflammatory cytokines. Similarly, LPS activates microglia in the brain by enhancing the non-selective nerve cell that promotes neuroinflammation. LPS seems able to enter the bloodstream from the digestive tract and activate astrocytes. The integrity of the BBB is inadequate, enabling LPS to pass through it and leading to inflammation in the brain.

3.1. The Cerebral Blood Barrier’s Involvement in the Brain Microbiota Intestines Axis in Alzheimer’s Disease

The intestinal epithelial barrier IEB is established by the mucosal barrier, which divides the host and microbes and permits only a small number of specific, extremely tiny molecules to pass through. Monolayer epithelial cells comprise this interface, and its IEB consists of diverse immunological cellular immunity that assists in the host’s defense and physiology. The functions and permeability of the IEB are primarily regulated by chemicals found in the body, including inflammatory agents, immune cells, bacteria, and metabolites. The vascular barrier of the gut (GVB), an acellular membrane underneath the epithelium, has just recently been established. GVB, the second line of defense, controls antigen translocation as well as prevents the entrance of intestinal microbiota.

The BBB consists of the CNS, segmental circulation of blood, pericytes, and brain endothelium. The condition, also known as “leaky gut syndrome”, affects IEB permeability and causes peripheral circulatory system inflammation and the expulsion of microorganism secretions (including endotoxins such as lipopolysaccharide). Peripheral monocytes activate during inflammation, penetrate the BBB, activate microglia, release inflammatory cytokines, and ultimately lead to neuronal inflammation in AD disease. Additionally, the development of neuroinflammation depends on the infiltration of peripheral lymphocytes, including 17 T-helper cells (4a).

3.2. Intestinal Disorders

Because the GIT has an important role in preserving gut homeostasis, problems related to any of its parts may exacerbate irritable bowel conditions. In UC, IBD and Crohn’s disease (CD) are featured as ongoing inflammation that may harm the colon and terminal ileum. The illness may affect all mucosal surfaces, and a histological examination will reveal granulomas in 50% of cases. In contrast, with UC, the colon is the organ affected and the inflammation only affects the surface mucosa. These illnesses are complicated and have both genetic and environmental components.
Evidence that the bacteria have an important role in IBD development includes the ability of antibiotics to lessen the severity of the condition [106], the genetic link between IBD and mutations within genes encrypting bacterial detectors TLR4, CARD4 (NOD1), CARD15 (NOD2), or TLR4 [107,108], or genes mutations related to cellular metabolism, which are essential for innate defense [109,110]. Whilst sought after, there is no concrete evidence that any pathogenic microorganisms cause IBD. Conversely, it has been shown that IBD individuals also have innate immunity to their own flora; however, healthy individuals exclusively do so in exposure to exogenous flora [111].

It is still unclear where these reactions start and whether there is a fundamental issue with intestinal absorption that allows germs that are typically excluded to enter. Furthermore, since the surrounding microenvironment gives DCs and macrophages a noninflammatory appearance, changes in this compartment affect the gut’s capability to sustain homeostasis by reducing immune cells’ capacity to control their proinflammatory potential [112–115]. Another inflammatory gastrointestinal condition that may be related to GIB impairment is IBS, which is a complex, multifaceted disorder. IBS is associated with psychological stress, most likely due to the delivery of corticotrophin hormone release (CRH) [116]. CRH can stimulate the immune cells, degranulate mast cells, and enhance intestinal absorption [117]. The IBS individuals’ rectal biopsies, independent of their IBS subtypes, contain an overwhelming number of mast cells, pointing to a link between mast cell activity and IBS [118]. It would be fascinating to learn if problems with BBB permeability could affect gastrointestinal disorders or vice versa.

Various investigations are conducted on animals. GF animals live in a sterile environment and are microbially lacking. These animals provide exceptional opportunities to investigate the role of the intestinal microbiota in the etiology of AD. The GF mice displayed abnormalities in the object recognition test, a non-spatial task, and had decreased CNS neurotropic factor levels in their hippocampi [40]. On the other hand, the GF mice showed a deficiency in their innate immune systems, which was shown by immaturity in the microglia. According to research by Fujii et al., mice that had the GM of an AD patient transplanted showed abnormal behavioral cognition [119].

The blood vessels in the CNS are notable for providing the BBB. Contrary to blood vessels in most tissues, which are porous and allow a relatively unrestricted stream of capillary ions, molecules, and cells through into tissue, arteries in the CNS detrimentally restrict the flow of ionic species, blood-related molecules, as well as cells in nerve tissue [120].

The BBB is an essential secondary barrier since the CNS tissue cannot regenerate after illness or injury. Stroke, trauma, and multiple sclerosis are a few neurological disorders that cause the barrier to collapse, and they play a significant role in the pathophysiology of these illnesses [11].

In disease, the BBB collapses. AD leads to the deposition of insoluble proteins, which causes microbleeds and hemorrhages in the brain. A plaque develops along the blood vessel walls [121]. The brains of AD patients have been found to have extracellular clumps of the possibly toxic Aβ protein and intracellular p-tau [122]. As a result, much evidence points to the importance of these proteins in the pathogenesis of AD.

Numerous epidemiological studies have also demonstrated a high linkage between AD and cardiovascular risk factors [123]. It has long been established that the BBB plays an important role in the pathophysiology of AD through brain clearance A, lymphocyte recruitment further into the brain, and inflammatory-response regulation [86]. It has been shown that the BBB leaks in people before the hippocampal shrinkage, which is frequently noticed in the initial stages of AD [124]. This shows that vascular abnormalities precede neurodegeneration. The extravasation of blood-related chemicals in the brain, which causes inflammation and immunological reactions, also frequently occurs in conjunction with AD [125]. The BBB protects the brain from blood-related derived substances, infections, and cells, which are required for proper information processing and neural activity. The post-mortem and scanning of brain research have shown a disruption of the BBB and blood-related accumulation of molecules in the cerebrospinal fluid, hippocampus, and
cortex. Additionally, research using murine models has demonstrated that blood-derived chemicals, such as thrombin, immunoglobulin, albumin, fibrinogen, prothrombin kinase-2, and thrombin, typically penetrate into the brain. However, damage to the neurons with enhanced BBB membrane permeability in the hippocampus accumulates in tissue as a result of BBB disruptions. Both barriers are essential as they restrict the admission of dangerous molecules and possess a significant impact on immunological recognition and homoeostasis preservation. Additionally, the BBB and IEB are essential for controlling the microbiota–intestine brain–gut axis [126].

4. Gut Microbiota Models of Animals in Alzheimer’s Disease

Microbiota gut animal models of AD give a real image of the GM, contributing to the disease’s etiology [127,128]. In an AD mouse model, neuroinflammation and amyloidosis have an impact on the variety of the GM [127]. Some studies included extracting 16S rRNA from bacteria (fecal APP transgenic mice samples) and showed that the microbiota of the guts of these animals differed from that of wild-type control mice [129]. Rikenellaceae increased due to these modifications, but Allobacillum and Akkermansia decreased. In a TgF344-AD transgenic rat model, a recent study showed a shift in the microbiota composition with age with a distinctive change in the genera Ruminococcus, Parasuiterella, Lachnoclostridium, Bifidobacterium and Butyricicoccus, thereby displaying gut microbiota changes in association with the progression of AD [130]. Recently, one of the animal models was implemented to study the neurodegenerative pathogenesis, which correlates with AD pathology-like neurofibrillary tangle (NFT) formation and reactive gliosis progression. The model was comprised of AD-like pathology with amyloid and neurofibrillary tangles in (ADLPAPT) transgenic mice and healthy wild-type (WT) mice. The microbiota of both groups were different. The frequent transfer and transplantation of the faecal microbiota from WT mice into ADLPAPT mice alleviated the formation of amyloid $\beta$ plaques and neurofibrillary tangles, glial reactivity and cognitive impairment [131]. One of the research groups from Washington University School of Medicine assessed the assumption that gut microbiota regulates tau pathology and neurodegeneration in an ApoE isoform-dependent manner. Tauopathy model mice (P301S tau transgenic mice) expressing human apoE isoforms (apoE3 and apoE4) were subjected to gut microbiota manipulation using two approaches: the first was being raised in sterile/germ-free conditions and the second was with an antibiotic treatment for a short period of time to change the spectrum of bacterial communities. The intentional gut microbiome dysbiosis resulted in a striking decline in tau pathology and neurodegeneration in an ApoE isoform-dependent mode. Together, these results support that gut microbiota regulates both amyloid plaque deposition and tau-mediated neurodegeneration (independent of amyloidosis) [132].

Obesity and type 2 diabetes have already been linked to a decreased abundance of Akkermansia, which are both known to increase the risk of dementia. Additionally, there was a bad connection between the abundance and presence of amyloid $\beta$ 42 peptide (A$\beta_{42}$) in the brain [129,133]. Cerebral A was considerably decreased in germ-free transgenic APP transgenic mice. Additionally, reduced microgliosis and modifications to the cytokine profile were seen. Recolonizing the mice with germ-free APP transgenic mice microbiota increased cerebral pathology, whereas using wild mouse microbiota had less effect [129]. Similarly, PD-modelling germ-free animals overexpressing-syn showed lower synmicroglial inclusions and activation than the controls. Reintroducing microbiota, particularly those from patients of PD donors, or adding SCFAs—by-products of microbial metabolism—restored these characteristics [134]. It is an intriguing observation that recolonization with germs from patients with PD worsens physical limitations.

5. Biomarkers: A Novel Diagnostic Approach for AD

The updated version of the 2011 guidelines by National Institute of Aging and Alzheimer’s, in association with the Alzheimer’s Association, has introduced a new research framework for AD. This framework is based on observational and international
research and provides separate diagnostic recommendation for the preclinical, mild cognitive impairment, and dementia stages of AD. The focus of this framework is on the use of biomarkers rather than solely relying on clinical symptoms for the diagnosis of AD in living individuals.

The AD-associated biomarkers are categorized into three groups: (a) β-amyloid protein, (b) pathological tau protein, and (c) neurogeneration, designated as [A/T/N] classification. It is important to note that this classification may evolve as new biomarkers are discovered. In some cases, biomarkers may not be available or their application may hinder specific research objectives. The discovery of reliable biomarkers for early detection and assessment of AD severity remains a critical need. Biomarker-based research must not be considered a one-size-fits-all approach for studying age-related cognitive impairment and dementia. Instead, biomarkers should be utilized based on their compatibility with the specific research objectives of each study.

A recent study has demonstrated a link between gut dysbiosis and changes in the intestinal epithelium, which may contribute to the development of degenerative diseases in the brain. Furthermore, there is a growing interest in exploring the potential of certain bacterial strains as biomarkers for AD. These newly discovered biomarkers, as outlined in Table 3, offer the possibility of transforming the diagnostic landscape by providing cost-effective and accessible screening methods. Integrating these biomarkers into diagnostic protocol has the potential to detect AD at an early stage, allowing for more effective intervention and treatment. The affordability and accessibility of these biomarkers could have a significant impact on public health by facilitating widespread screening initiatives and promoting early intervention strategies. Ongoing research aims to explore these biomarkers in diverse populations and incorporate them into routine clinical practice, potentially reshaping the approach to AD diagnosis and management.

**Table 3. Microbiome-based biomarkers in humans.**

<table>
<thead>
<tr>
<th>S. No</th>
<th>Biomarker(s) Proposed</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
</table>
| 1.    | Cortisol              | • Diminished global cognitive performance  
   |                      | • High disease intensity at standard level  
   |                      | • Low episodic memory                  | [135] |
| 2.    | Plasma Aβ + gut microbiota | • The CN+ individuals as compared to CN− individuals exhibited  
   |                      | • Significant increase in phylum bacteroidetes and significant decrease in Firmicutes and class Deltaproteobacteria. | [136] |
| 3.    | SCFA-producing microorganisms | • Increase in Clostridium leptum and decrease of Eubacterium ventriosum group spp., Lachnospiraceae spp., Marvinbryantia spp., Monoglobus spp., Ruminococcus torques group spp., Roseburia hominis, and Christensenellaceae R-7 spp. with a prominent alteration in amyloid positivity  
   |                      | • Abundances of the family Lachnospiraceae, Ruminococcaceae in AD | [137,138] |
| 4.    | Gut microbiota composition + diet quality scores + serum miRNA | • Decrease in microbial diversity, Faecalibacterium, Ruminococcaceae, and Alipstes in MCI compared to controls  
   |                      | • Gut microbiota play an important role in determining the integrity and functionality of intestinal barrier | [139,140] |
| 5.    | Faecalibacterium, Bifidobacterium Pseudomonas | • Decreases microbial diversity in AD compared to controls  
   |                      | • Decrease in butyrate-producing bacteria (Faecalibacterium) in AD  
   |                      | • Increase in lactate-producing bacteria (Bifidobacterium) in AD  
   |                      | • A combination of bacterial genera (Faecalibacterium and Pseudomonas) and four metabolites (N-Docosahexaenoyl GABA, 19-Oxoaandrostan-4-ene-3,17-dione, Trigofoenoside F and 22-Angeloylbarringtogenol C) was able to discriminate AD from normal control | [141,142] |
Table 3. Cont.

<table>
<thead>
<tr>
<th>S. No</th>
<th>Biomarker(s) Proposed</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
</table>
| 6.    | Indole-3-pyruvic acid five SCFAs and Tryptophan | • Decrease in tryptophan metabolites in MCI and, more pronounced, in AD compared to controls  
• Significant decrease in SCFAs (formic acid, acetic acid, propanoic acid, 2-methylbutyric acid, and isovaleric acid) in AD compared to controls; Decrease in MCI compared to controls  
• TRP degradation and simultaneous altered kynurenines levels were found in plasma of AD patients | [143,144] |
| 7.    | SCFAs and LPS | • Increase in blood LPS, acetate and valerate, proinflammatory cytokines, and biomarkers of endothelial dysfunction in dementia  
• Decrease in butyrate and the anti-inflammatory cytokine IL10 in dementia  
• Specific bacterial genera are associated with immune and endothelial microbiota–gut–brain axis (MGBA) mediators, and these are associated with amyloid cascade markers in sporadic AD. | [145,146] |
| 8.    | Mycobiome signatures | • Increase in Genera Botrytis, Kazachstania, Phaeoacremonium, Cladosporium, and families Sclerotiniaceae, Phaffiomyctecae, Trichocomaceae, Cystofibosidellaceae, and Togniniacae in MCI compared to CN  
• Meyerozyma in MCI < CN  
• Different correlation patterns with AD markers and GM are displayed by specific fungal species (Debariomyce, Sarocladium, Filobasidium, Candida, and Cladosporium)  
• Significantly different abundance of the Dipodascaceae family. This reinforces that several microbial alterations participate to metabolic and proinflammatory imbalances that, consequently, can enhance the development of AD | [147] |
| 9.    | Lachnospiraceae NK4A136 group, DAO, sCD14 | • Significant decrease in Lachnospiraceae, genus Lachnospiraceae NK4A136 group in dementia.  
• Decrease in Eubacterium rectale in dementia.  
• Increase in DAO and sCD14 in dementia.  
• Faecalibacterium prausnitzii was associated with mild dementia; Lactobacillus anguillorae was associated with moderate dementia; Clostridium clostridiforme and Streptococcus salivarius were associated with Severe dementia  
• Associations were detected between the phylum Baciilota (Lachnospiraceae, Ruminococcus torques, Roseburia hominis, Lachnoclostridium, Marvinbyranta spp.) and the levels of Aβ and tau in both plasma and CSF | [148,149] |
| 10.   | CCK | • Increases in CCK had a strong relationship associated with increase in tau levels  
• Increase in CCK was related to increased global and memory scores  
• Increase in CCK was related to increased gray matter volume  
• CCK is a multi-functional peptide hormone. Impaired release and/or expression of CCK, CCK-1Rs and CCK-2Rs could contribute to neurodegenerative processes in AD | [150,151] |

AD, Alzheimer’s disease; MCI, mild cognitive impaired; CN, cognitively normal; CN−, Aβ-negative cognitively normal; CN+, Aβ-positive cognitively normal; GM, gut microbiome; CSF, cerebrospinal fluid; LPS, Lipopolysaccharides; SCFAs, short chain fatty acids; Aβ, amyloid-β; CCK, Cholecystokinin; DAO, diaminooxidase; sCD14, soluble CD 14.

6. Targeted Therapy for AD: Amelioration of Microbiota

A major concern of antibiotic use is the long-term alteration of normal healthy GM and the horizontal transfer of resistance genes that could result in a reservoir of organisms with a multidrug-resistant gene pool.
GM regulation is fundamental for the well-being of human health; its deregulation in AD patients is established. For the maintenance of healthy GM, diet is an essential factor. The onset of AD and dietary pattern is linked, as proposed by many studies, conferring diet as an adaptable risk element [152,153]. The contributing factors suggested in the pathogenesis of AD reflecting dysbiosis are poor dietary habits and inflammatory response. Well-preserved cognitive functions with anti-inflammatory properties have been associated with the Mediterranean diet, which is characterized by consumption of mainly vegetables, fruits, cereals and lean meat with reduced high-fat diet intake [154]. The MedDiet is endowed with fibers, minerals, and vitamins (especially B complex) that influence the microbiota. Ghosh et al.’s study of the effect of one year MedDiet on the GM in 612 non-frail subjects from five European countries demonstrated an alteration in gut microbiome in elderly subjects with an improvement in their health status [155]. Similar studies by Hoscheidt et al. provided evidence that the MedDiet encourages metabolic and brain health during mid-life as compared to the Western diet. The diet response during middle age is important to take into account as this phase may involve early pathophysiological processes that increase the AD risk [156].

Another dietary pattern supporting neuroprotective behavior is believed to be the KD. It is a very high-fat, low-carbohydrate diet that brings the body into a state of ketosis by implicating a fasting-like effect [157]. Neuronal loss by apoptosis is reduced by low-serum glucose and high-serum fat levels. This diet attunes the upregulation of hippocampal genes coding for mitochondrial enzymes, thus providing alternative energy substrates [158]. Moreover, KD reduces oxidative stress and inflammatory response and encourages neurotrophic factors besides raising the GABA-to-glutamate ratio and activation of ATP-sensitive potassium channels. Such changes contribute to the improvement of brain metabolism and KD is gaining attention as a probable therapy for neurodegenerative disorders like AD [159]. Ketones have been considered as endogenous factors protecting AD. The neuroprotective mechanism of ketones in AD is attributed to the blockage of intracellular Aβ-42 buildups in mouse models [160]. The involvement of Aβ-42 in the pathogenesis of AD has paved the way to screen those formulations, which will selectively reduce the Aβ 42 either by reducing its formation or increasing clearance without affecting the normal protein processing and formation.

Early interventions with KD can increase useful microbiota and improve brain vascular functions, and intermittent fasting (IF) reduces insulin resistance neuroinflammation and increases metabolic regulation and brain-derived neurotrophic factor (BDNF) levels [161]. Dietary interventions are usually more beneficial and safer than pharmaceutical therapies due to their economical and easy-handling properties.

6.1. Probiotics

Probiotics are a combination of live microorganisms (bacteria and yeast), inhabitants of our body, used to improve the healthy microbiota, thereby improving the life of the host when ingested in adequate amounts [162]. They have shown wider effects on human health, including correcting immunity, hormone functions, metabolic functions, regulating pH levels, preserving the integrity of intestinal lining, delaying aging and enriching the brain-derived neurotrophic factor [163]. These neurotrophic factors are protein factors that find important roles in neurology by making the survival and differentiation of neurons possible. The most fascinating effect of probiotics on the host is in improving brain health, behavior and functioning. The clinical trials have demonstrated restoration of GM, restoration of the integrity of BBB, diminished oxidative stress, improved cognitive decline, lowered neuroinflammation and improved insulin sensitivity by supplementing microbiota. The probiotics used to rectify the misbalance of the microbiota-regulated gut–brain axis are termed psychobiotics [164]. Probiotic alteration influences the onset of AD due to the deregulation of the microbial picture. This imbalance in AD has shown a reduction in Verrucomicrobia, Proteobacteria, Actinobacteria, Firmicutes, Bifidobacterium bacteria and an increase in Bacteroides and Tenericutes. It is speculated that changes in GM can cause...
colonization of internal pathogens, leading to increased gut permeability. A study by Wu et al. 2017 on the Drosophila AD model established that enterobacteria infection aggravates AD progression by influencing immune hemocyte recruitment to the brain [165]. There is evidence supporting probiotic administration with its superior effects on the gut–brain axis. In a randomized controlled trial, a mixture of probiotic consumption in health volunteers for 4 weeks significantly lowered sensitivity to a sad mood [166]. Benton et al. 2007 reported improved mood upon yogurt consumption for 3 weeks in healthy subjects [167]. Probiotics also exhibit immunological benefits that seem to be strain-specific, while strain specificity is well recognized in AD. Therefore, not all probiotics have psychobiotic potential, unlike a few, such as *Bifidobacterium* and *Lactobacillus*, which are frequently used as psychobiotics [168]. More research is needed to screen the effective probiotic strains in the management of AD.

6.2. Prebiotics

Prebiotics are nutrients (plant fibers) degraded by GM in the lower part of the GI tract. Intestinal bacteria feed on them and the degradation products are short-chain fatty acids. The short-chain fatty acids (SCFA) enter the systemic circulation and can affect other organs besides GI tract. Fructo and galacto-oligosaccharides are notable prebiotics used alone or in combination with probiotics that have beneficial effects on human health [169]. Prebiotics act as substrates and are fermented by gut bacteria like *Bifidobacteria* and *Lactobacill*, increasing the anti-inflammatory metabolite machinery. Evidence suggests prebiotics’ role in improving neurological disorders in rat models by reducing the raised cortisol response and altered sentimental bias in normal volunteers [170]. The amelioration of cognitive deficits and neurodegeneration in the AD transgenic mice model was reported by the administration of fructooligosaccharides (FOS). There was an upregulation of synapsin 1, PSD-95 with a reduced phosphorylated level of JNK, reduced GLP-1R and increased levels of GLP-1, signifying the favorable effects of FOS against AD by governing the gut microbiota-GLP-1/GLP-1R pathways [171]. Sodium oligomannate (GV-971), derived from marine sources, was tested in a 24-week double-blind, randomized, placebo-controlled phase II clinical trial in China. There was a cognitive improvement as attributed to the decline of ADAS-cog12 (Alzheimer’s Disease Assessment Scale–cognitive subscale 12-item) and improvement in ADCS-ADL (Alzheimer’s Disease Cooperative Study–Activities of Daily Living) and NPI (neuropsychiatric inventory) scales [173]. The study shows GV-971 as a novel agent that may enhance cognition in AD by reconstituting the dysbiosis of GM. Overall, the literature suggests personalized prebiotic administration, which acts by modulation of GM, may speak for a new therapeutic approach for AD.

6.3. Fecal Microbiota Transplantation (FMT)

FMT is one of the therapeutic procedures in the alleviation of AD with minor precautions, as the entry of live microorganisms or metabolites is to be taken care of. One the study used the AAPswe/PS1dE9 Tg mouse model to testify to the action of FMT for the treatment of AD. GM and SCFA analyzed by 16S rRNA-sequencing and NMR depicted improved cognitive deficits, reduced Aβ deposition, and increased synaptic plasticity and reduced neuroinflammation. A study on 82-year-old AD patients with recurrent *Clostridium difficile* infection intervened by FMT infusion showed improvement in AD symptoms [174]. Zhan et al. 2018 observed antibiotic treatment diminished cognitive function in wild mice and fecal intake after improving memory and spatial learning [175]. These studies suggest cognitive decline is associated with antibiotics, which can be reversed with FMT. Conversely, few studies suggest a reduction in Aβ deposition after antibiotic administration. When administered with an antibiotic cocktail, Dodiya et al., 2019, observed a disturbed microbiome with lowered Aβ plaque pathology and astrogliosis in male mice [176]. Hence FMT may
act as a potential therapeutic for AD and other neuroinflammatory conditions. However, the available literature is still meager and conflicting studies should be taken into account. Nevertheless, further studies involving double-blinded randomized controlled trials are to be carried out to further cross-validate the action of FMT in neurodegenerative disorders.

7. Conclusions

The gut–brain axis plays a significant role in regulating the body’s physiological processes, including food intake, glucose and fat metabolism, insulin secretion, and responsiveness. The gut microbiota (GM) communicates with the brain via biochemical signaling, and GM dysbiosis can impact the digestive system and the functioning of the central nervous system (CNS). Furthermore, GM dysbiosis can lead to the generation of mediators of proinflammatory responses connected to the initiation of AD. Maintaining the normal integrity of the BBB is crucial in preventing harmful substances released from the GM from entering the CNS and causing damage.

The reduction in the activity of choline acetyl-transferase in the cerebral cortex and hippocampus is the most consistent molecular insult that leads to AD changes. Glial cells are also found to play an important role in reacting with tau and amyloid pathology in AD patients. The presence of plaques and tangles in the brain meets the histopathologic diagnostic standards for AD in 90% of AD-diagnosed cases, as indicated by anatomo-clinical studies. However, some nondemented elderly patients may also qualify for a pathologic diagnosis of AD. These findings highlight the complex and multifactorial nature of AD, with implications for developing more effective diagnostic and therapeutic strategies. There is strong evidence supporting the role of Aβ in contributing to AD. Aβ multimeric aggregates are suspected of contributing to the disease, forming long fibrils and aggregates known as plaques, the neuropathological hallmark of AD. The amyloid cascade hypothesis plays an important role in explaining the pathogenesis of AD, and mutations associated with the familial type of AD increase Aβ production or modify its production rate. Aβ has diverse toxic mechanisms that contribute to its toxicity, including oxidative stress, mitochondrial diffusion, membrane permeability, inflammation, synaptic changes, and excite-toxicity. β-sheet-rich fibrils formed by aggregation of synthetic Aβ have been hypothesized to cause neurodegeneration in AD, and soluble Aβ oligomers are more cytotoxic than insoluble fibrillary aggregates. Overall, the evidence supports the contribution of Aβ to AD pathogenesis, and targeting Aβ production or accumulation is a promising approach for treating AD. Further research is needed for a better understanding of the signaling pathways and underlying mechanisms that will open the way for identification of new targets and holistic intervention of AD.

Alternative conclusion: The gut–brain axis significantly regulates physiological processes, and GM dysbiosis can impact CNS functioning, contributing to proinflammatory mediators associated with AD initiation. Maintaining the BBB’s normal integrity is crucial in preventing harmful substances from the GM from entering the CNS. Molecular insults, such as reduced choline acetyl-transferase activity and glial cell reactions, play pivotal roles in AD pathogenesis. Plaques and tangles meet diagnostic standards in most AD cases, emphasizing the complex and multifactorial nature of AD. Strong evidence supports β-amyloid’s contribution to AD, with diverse toxic mechanisms. Targeting Aβ production or accumulation shows promise in AD treatment. However, further research is crucial for a holistic understanding and identification of new therapeutic targets for AD intervention.

**Funding:** No funding was available for this work.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** This review article did not generate any data or materials used in the execution of this work; instead, all referenced literature is listed in the bibliography.

**Conflicts of Interest:** The authors declare no competing interests.

**References**


19. Strandwitz, P. Neurotransmitter modulation by the gut microbiota. *Brain Res.* 2018, 1693, 128–133. [CrossRef]


J. Dement. Alzheimer’s Dis. 2024, 1


Raven, E.P.; Lu, P.H.; Tishler, T.A.; Heydari, P.; Bartozikis, G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer’s disease detected in vivo with magnetic resonance imaging. *J. Alzheimer’s Dis.* 2013, 37, 127–136. [CrossRef] [PubMed]


Nagarajan, A.; Srivastava, H.; Sun, L.Y. Characterizing the gut microbiome changes with aging in a novel Alzheimer’s disease rat model. *Aging* 2023, 15, 459–471. [CrossRef]


**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.